Literature DB >> 22725706

Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy.

Bernard Waeber1, Corina Rotaru, François Feihl.   

Abstract

INTRODUCTION: Diuretics play a pivotal role in the management of hypertension. A large experience has been accumulated with indapamide , a long-acting thiazide-like diuretic that lowers blood pressure (BP) primarily through its natriuretic diuretic effect. Some of its long-term antihypertensive efficacy may be due to calcium antagonist-like vasorelaxant activities. Indapamide has protecting effects in a variety of conditions associated with high cardiovascular risk, such as diabetes, left ventricular hypertrophy, nephropathy and stroke. It is highly effective in lowering BP, whether given alone or in combination. Indapamide is well tolerated and has the advantage of having no adverse impact on glucose and lipid metabolism. Today, thiazide-like diuretics are regarded more and more as preferred drugs, when diuretic therapy is required to lower BP. AREAS COVERED: The aim of this paper is to review the experience accumulated with indapamide. It is limited to clinical studies that are relevant for the everyday management of hypertensive patients, whether or not they exhibit cardiovascular or renal disease. EXPERT OPINION: Indapamide, because of its well-documented beneficial effects on cardiovascular and renal outcomes, represents a safe and valuable option for treating patients with high BP. There is, however, still room for new trials evaluating the combination of this diuretic with other types of antihypertensive drugs, in particular a calcium antagonist such as amlodipine. There is also the need to compare the indapamide-perindopril and indapamide-amlodipine combinations, in terms of antihypertensive efficacy, tolerability and effects on target organ damage and, ideally, on cardiovascular mortality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22725706     DOI: 10.1517/14656566.2012.698611

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  10 in total

Review 1.  Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention.

Authors:  Samuel J Mann; Michael E Ernst
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

2.  Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes.

Authors:  T A Netchessova; A P Shepelkevich; T V Gorbat
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-12-20

3.  Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study.

Authors:  Yuri Aleksandrovich Karpov
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

4.  Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR.

Authors:  Dénes Páll; Ildikó Szántó; Zoltán Szabó
Journal:  Clin Drug Investig       Date:  2014-10       Impact factor: 2.859

5.  Powerful diuretics: A common denominator in landmark hypertension and type 2 diabetes mellitus trials.

Authors:  Kaberi Dasgupta; Ruth Sapir-Pichhadze; Nadia Khan
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-12-18       Impact factor: 3.738

6.  Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study.

Authors:  Uday Jadhav; Jagdish Hiremath; Deepak J Namjoshi; Vinod K Gujral; Kamlakar K Tripathi; Mohammad Siraj; Paramesh Shamanna; Michel Safar
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

7.  Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria).

Authors:  Olivier Hanon; Laure Caillard; Edouard Chaussade; Intza Hernandorena; Clemence Boully
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-07-18       Impact factor: 3.738

8.  Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO trial.

Authors:  Csaba Farsang
Journal:  Adv Ther       Date:  2014-02-20       Impact factor: 3.845

Review 9.  Which thiazide to choose as add-on therapy for hypertension?

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  Integr Blood Press Control       Date:  2014-07-30

10.  Functional inhibition of urea transporter UT-B enhances endothelial-dependent vasodilatation and lowers blood pressure via L-arginine-endothelial nitric oxide synthase-nitric oxide pathway.

Authors:  Yi Sun; Chi-Wai Lau; Yingli Jia; Yingjie Li; Weiling Wang; Jianhua Ran; Fei Li; Yu Huang; Hong Zhou; Baoxue Yang
Journal:  Sci Rep       Date:  2016-01-07       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.